ENGOT-EN1/FANDANGO: A randomized double-blind phase II trial of combination chemotherapy with nintedanib or placebo for patients with endometrial cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-000193-38

Femme Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Primary objective: To compare Progression free survival (PFS). Progression Free Survival (PFS) is de-fined as the time from randomization until disease progression or death by any cause. The progression events are defined by RECIST 1.1 criteria


Critère d'inclusion

  • Histological confirmed endometrial cancer. (FIGO 2009) stage 3C2 or stage 4 or relapsed after adjuvant therapy for stage 1-3 disease